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Abstract
The monoclonal antibody VN04-2 was previously shown to protect mice against lethal A/Vietnam/
1203/04 H5N1 virus challenge when administered pre- and post-infection. In this study, we
characterized the binding requirements of this antibody using direct binding to hemagglutinin and
neutralization assays with H5N1 virus-like particles (H5N1-VLP) of eight recent H5N1 strains
representing the major mutations within the 140s antigenic loop. Binding was clade independent
and 3 mutations within this antigenic region are required before escape is possible, suggesting that
apart from the H5N1 viruses circulating in Indonesia, VN04-2 may provide protection against
H5N1 viruses from all other regions.
Findings
In 1997, human disease was first reported due to direct
transmission from poultry of highly pathogenic avian
influenza A virus (HPAI) of the subtype H5N1, resulting
in the death of 6 of the 18 infected individuals [1-3].
Increased geographical distribution (H5N1 has been
reported in a variety of birds from over 50 countries) cou-
pled with continued evolution of H5N1 viruses and an
immunologically naïve human population highlight the
pandemic potential of these viruses [4,5]. Virus spread
among the human population has been limited and
largely remains the result of direct bird-to-human trans-
mission. As of mid-January 2008, there have been 349
reported cases of human H5N1 infection with a high mor-
tality rate resulting in the death of 216 individuals [6].
Recently, we and others have reported therapeutic efficacy
of passive immunization in a HPAI H5N1 mouse model
with either humanized mouse mAb, equine F(ab')2, or
human mAb, highlighting its potential as a viable treat-
ment option in human cases of H5N1 [7-9]. Indeed, sur-
vival of a person infected with HPAI H5N1 has been
reported after treatment with convalescent plasma [10]. A
potential drawback to the use of specific mAb is that the
high mutation rate of influenza viruses particularly in the
antigenic regions means that escape from the protective
effect of these antibodies may be rapid. In the case of our
humanized mAb VN04-2 (also termed 15A3) specific for
the 140s antigenic loop, hemagglutination inhibition
(HI) assay data suggested an absolute requirement for
lysine at position 140 [8,11]. However, mutation of
H5N1 viruses outside of antibody binding sites have been
shown to negatively affect the performance of the viruses
in HI assays, suggesting that in some cases a negative HI
assay result may be more a limitation of the assay rather
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than lack of antibody binding [12]. Here we evaluated
binding of VN04-2 to a variety of H5 hemagglutinins
(HA) independent of the HI assay, to determine the actual
effects mutations in this region of the HA gene has on
antibody binding and the utility of the antibody for pro-
tection against recently circulating H5N1 viruses.
The mAb VN04-2 was raised against the HA of A/Vietnam/
1203/04, therefore to select the HAs to be used in this
study, we aligned all the HA sequences from H5N1 viruses
isolated throughout 2005 and 2006, that were deposited
into the Influenza Virus Resource and was maintained by
NCBI, against this HA [13]. Focusing on mutation within
the 140s loop antigenic region, the HA sequences could
be divided into eight groups, and a representative of each
of these was selected to be used in the antibody binding
analysis (Table 1). The cDNAs encoding the HA1 subunits
of the selected HAs were produced by a combination of
PCR based methods and the fidelity of each clone was
confirmed by sequencing. In order to produce the HA pro-
teins, we used the recombinant baculovirus expression
method described for determination of the H5 HA struc-
ture, where the transmembrane domain had been
replaced by the 'foldon' trimerization sequence, allowing
for expression of soluble HA trimers which could be puri-
fied by virtue of the carboxyl terminal hexa-histidine tag
[14]. Following introduction of the foldon sequence into
the HA2 of A/Vietnam/1203/04 and insertion into plas-
mids containing each of the HA1s listed in table 1, recom-
binant baculoviruses were produced and used to infect Sf9
insect cells. All nine of the HA-foldons could be purified
from culture medium using talon affinity resin and cleav-
age into HA1 and HA2 subunits with trypsin indicated
that the proteins were correctly folded (data not shown).
To examine the ability of the humanized antibody VN04-
2 to bind to the selected HAs, ELISA was performed. Fig-
ure 1 shows the level of binding detected with 1 ug/mL
VN04-2 antibody and several serial dilutions, after the
various HA-foldons were coated onto ELISA plates at 500
ng/well. Highest signal was observed with the immuno-
gen HA from A/Vietnam/1203/04, while the HAs from A/
Indonesia/5/05 and A/Ck/Indonesia/R60/05 were unable
to bind VN04-2 at all, suggesting that 3 mutations within
the 140s loop antigenic site are required to escape anti-
body binding, a conclusion supported as the remaining
HAs showed binding of VN04-2 albeit at varying degrees.
Interestingly, the HA from A/Dk/Vietnam/376/05 which
only contains mutations within the 140s loop showed
similar binding characteristics to that of A/Vietnam/1203/
04. Therefore, the amino acids within the 140s loop may
be the main determinants of antibody binding for VN04-
2, but residues outside of this region may also contribute
to the overall antibody binding affinity. Previous studies
with H3N2 influenza A virus have indicated that antibod-
ies against the 140s loop antigenic site with association
constants (KA) in the 106 M-1 range can bind HA by ELISA
and exhibit neutralizing efficacy [15]. Therefore to defini-
tively measure the actual binding kinetics of VN04-2 to
the various HAs that showed binding in the ELISA assay,
we also measured the affinity of VN04-2 for the various
HA-foldons using Biacore SPR analysis. The antibody
showed a range of association constants for the HAs with
the highest calculated against A/Vietnam/1203/04 (2.63 ×
108 M-1) and the lowest calculated against the lowest
ELISA binding A/CK/Ivory Coast/1787/06 (1.93 × 107 M-
1), indicating good agreement between the ELISA data and
the actual antibody/HA KA  (Table 2) Together, these
results deduce that the absolute requirement for lysine at
Table 1: Position of mutation in the selected HA1s compared to A/Vietnam/1203/04a
Amino acid position
Virus Cladeb 140s Loop 150s Loop
9 41 2 41 2 91 3 61 3 71 3 81 4 01 4 11 5 41 5 51 5 61 8 9
A/Vietnam/1203/04 1 D S L P Y Q K S N S T K
A/DK/Vietnam/376/05 1 . ..... NP ....
A/BhGs/Qing Hai/65/05 2.2 N D S ...R .. NAR
A/CK/Ivory Coast/1787/06 2.2 N D S . H . R . DNAR
A/Zhe Jiang/16/06 2.3.4 N D S ...TP. N ..
A/DK/Guangzhou/20/05 9 . NS ..L . P . NA .
A/Indonesia/CDC597/06 2.1.2 N D ...LR.. N . R
A/Indonesia/5/05 2.1.3 S D S ..LSP...R
A/CK/Indonesia/R60/05 2.1.1 N D S S . LDP ..AR
a residues similar to A/Vietnam/1203/04 are marked by a period
b Clade nomenclature as suggested by WHO [19]Virology Journal 2008, 5:80 http://www.virologyj.com/content/5/1/80
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residue 140, as indicated previously by the HI assay, was
most likely due to assay limitations rather than the actual
binding properties of the antibody. However, as limited
mutation in the 140s antigenic loop and elsewhere lowers
the affinity of VN04-2 interaction with HA, we wanted to
determine if the lower affinity correlated to a loss of neu-
tralization.
Recently, virus-like particles (VLP) built on a retroviral
core particle, harboring the surface proteins of Venezuelan
equine encephalitis virus and H5N1 have shown their
potential as vaccine candidates and also through inclu-
sion of either luciferase or GFP reporter genes, utility as a
substitute for live virus in cell based neutralization assays
[16-18]. The VLP utilizes the core particle of the moloney
murine leukemia virus and as it is non-replicative, is ide-
ally suited for pseudotyping of high containment viruses
such as H5N1. To enable expression of H5N1-VLPs, we
cloned the HA1 cDNAs described in table 1 together with
HA2 of A/Vietnam/1203/04 into the CMV promoter
driven expression vector, pXJ and the N1 neuraminidase
(NA) of A/Vietnam/1203/04 into pCI (Promega). The
plasmids encoding the core particle and GFP reporter
gene, pVPack-GP and pFB-hrGFP respectively were pur-
chased from Stratagene. Following introduction of the
plasmids into HEK293, the production of H5N1-VLPs
was confirmed by immunoblots and observation of GFP
in MDCK cells after incubation with the HEK293 culture
medium (data not shown).
To determine the ability of VN04-2 to neutralize transduc-
tion of the various H5N1-VLPs, HEK293 culture superna-
tants were incubated with 2 ug/mL VN04-2 for 60 min
prior to the addition to MDCK, and 3 days later the
number of cells expressing GFP was determined by flow
cytometry. As highlighted in table 3, except for the H5N1-
VLPs produced using the HAs from A/Indonesia/5/05 and
A/Ck/Indonesia/R60/05, VN04-2 was able to neutralize
the transduction of all the H5N1-VLPs tested. It is worth
noting that HAs which exhibited the lowest affinity for
VN04-2 also exhibited less neutralization, indicating a
correlation between direct binding affinity and effective-
ness of viral neutralization for a known neutralizing anti-
body. In addition, when we used the culture supernatants
incubated with VN04-2 in a HI assay, inhibition was only
observed when the H5N1-VLPs HA had aspartic acid resi-
due 94 (Table 3), which is in agreement with the HI data
reported by Chen et al, presented in table 1[11]. Taken
together the results support the hypothesis that the abso-
lute requirement of lysine at residue 140 was due to a lim-
itation of the assay and not the antibody. While in vitro
data does not always reliably predict in vivo efficacy [7].
The demonstrated in vivo efficacy of VN04-2, coupled
with the relative insensitivity of this antigenic region to
the low pH induced conformational changes of HA, prior
to fusion as seen in H3N2 [15]: we believe that in this
case, in vitro binding data could be indicative of in vivo
efficacy. However, this can only be confirmed with empir-
ical data.
In conclusion, our results show that the protective
humanized antibody VN04-2 we have previously
described is capable of tolerating 3 mutations within its
epitope, the 140s loop and that residues outside of this
loop while not being major determinants of antibody
binding do affect the affinity of the antibody binding to
HA. In addition, our results indicate that the previous
requirements for VN04-2 binding derived from HI assay
data may have been due to assay limitations rather than
the actual antibody binding and adds to an increasing
amount of evidence questioning the usefulness of HI
assays as a measure of neutralization, or for epitope map-
ping. The HA clones described here were representative of
the antigenic drift observed during 2005 and 2006 within
this antigenic region, and is still the case for H5N1 strains
isolated throughout 2007, suggesting that apart from the
Table 2: Equilibrium association (KA) and dissociation 
(KD)constants of VN04-2 with HA
Virus of HA-Foldon KA (M-1) KD (M)
A/Vietnam/1203/04 2.63 × 108 3.8 × 10-9
A/DK/Vietnam/376/05 9.72 × 107 1.03 × 10-8
A/BhGs/Qing Hai/65/05 3.08 × 107 3.25 × 10-8
A/CK/Ivory Coast/1787/06 1.93 × 107 5.17 × 10-8
A/Zhe Jiang/16/06 2.36 × 107 4.24 × 10-8
A/DK/Guangzhou/20/05 5.46 × 107 1.83 × 10-8
A/Indonesia/CDC597/06 3.38 × 107 2.96 × 10-8
Affinity of VN04-2 against various HA-foldons determined by  ELISA Figure 1
Affinity of VN04-2 against various HA-foldons deter-
mined by ELISA. Purified HA-foldons from the indicated 
H5N1 viruses (outlined in table 1) were used to coat ELISA 
plates and incubated with VN04-2 (1 ug/mL) or its 2 fold 
serial dilutions, bound antibody was detected with anti-
human IgG conjugated to HRP and visualized using TMB. 
Data shown are the averages from two independent experi-
ments.
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H5N1 viruses circulating in Indonesia, VN04-2 may pro-
vide protection against H5N1 viruses from all other
regions.
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